Beijing Prime Gene

Beijing Pri-gene Biotech is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of innovative cell and gene therapies. The company primarily focuses on chimeric antigen receptor (CAR) technologies, including CAR-T and CAR-NK therapies, to treat hematological malignancies and solid tumors. Its lead candidate, PRG-1801, is a BCMA-targeted CAR-T therapy currently in Phase 1/2 clinical trials for relapsed or refractory multiple myeloma. Pri-gene leverages proprietary platforms for cell engineering and lentiviral vector production to create high-quality, accessible immunotherapies. With integrated R&D and manufacturing capabilities, the company is positioned as a significant player in the Chinese cell therapy landscape.